The Art and Science of Drug Hunting | Christoph Lengauer, CSO & Co-Founder of Curie.bio
Nucleate PodcastShow Notes
In this episode, we sit down with Christoph Lengauer, co-founder of Curie.Bio, a venture creation firm, and former founding CSO and Chief Drug Hunter at Blueprint Medicines.
Christoph's non-linear career began in Austria as the first in his family to attend college, leading him to pursue human genetics after reading a book on cancer. Despite finding success in academia, he quit science, only to return with a focus on creating medicines, which he considers the ultimate impact. This pivot led him to the best molecular genetics cancer lab in the world, the lab of Bulgin at Johns Hopkins, where he stayed for 12 years and helped lead the lab for nine.
Christoph shares his philosophy on "responsible practice" in drug discovery, a path that avoids the slow, "fat way" of big pharma and the reckless "slim way," by taking measured risks and doing only the necessary work to get to meaningful results the fastest. He argues that successful drug hunting is found in the "margin," defined by cultural elements such as being honest, humble, and transparent, and being surrounded by a supportive team, not just technical strength or intelligence.
We dig into his time at Third Rock Ventures, where he broadened his approach from a narrow focus on kinases to diversifying drug discovery across different target classes and therapeutic areas, and how this experience informed the creation of Curie.Bio. He explains Curie.Bio's model, which centers on freeing the founders, operating with low fixed costs, and providing fractional access to over 100 experienced drug hunters, helping companies like Forward Therapeutics reach the clinic in approximately three years.
Finally, Christoph offers practical advice for founders operating in challenging market environments: have a clear trajectory towards "meaningful clinical activity data" using a $7 million to $15 million budget to reach a development candidate, and an additional $30 million to $50 million to reach that data. He stresses that the biggest mistake a founder can make is thinking they can succeed alone. He advises academic founders to avoid being secretive, to share their ideas with trusted people, and to explain their ideas in "plain English" to clearly articulate the problem they are solving.
More from Nucleate Podcast
The Nucleate Podcast welcomes Matias Serebrinsky, co-founder of Psymed Ventures. Raised in Argentina by a physician father and an economist mother, he shares how his early life influenced his comfort with risk and his drive to do work that helps others. Matias shares his path from Sony marketing to starting CookUnity, and eventually to building a venture fund focused on brain and mental health.
In this episode of the Nucleate Podcast, Dr. Jo Viney, co-founder, president, and CEO of Seismic Therapeutic, shares her trajectory from academic immunology training in London to major biotech companies and startup leadership. She discusses how early clinical lab exposure to autoimmune patients sparked her passion for translational science and highlights why the Boston ecosystem is an ideal place to launch biotech startups due to its unparalleled funding, incubator space, and collaborative peer networks. She also reflects on the lessons learned from co-funding Pandion Therapeutics—including how following surprising data led to a major asset acquisition by Merck—and describes the bittersweet feeling of handing off a company she helped build.
In this episode of the Nucleate Podcast, Joe Betts-LaCroix, co-founder of Retro Biosciences, traces his path from Silicon Valley hardware startups to longevity biotech, explaining that a liquidity event from his first company prompted him to reflect on the limited real-world impact of most tech products compared to medicine, which almost always meaningfully helps people. He describes Retro's approach to navigating biotech regulation through a "daughter test" – asking whether a given regulatory requirement is one he'd genuinely want applied if it were his own family member's treatment on the line. He then explains why the company has set an ambitious but achievable mission of extending healthy human lifespan by 10 years, framing it as a "right-sized" goal for a venture-backed startup.
She started out as a small-town GP in South Africa with zero idea a "biotech industry" even existed. Three decades later, Deborah Dunsire had led the launch of Gleevec — the first targeted cancer therapy ever approved — steered Millennium Pharmaceuticals through an $8.8 billion acquisition, and run two more companies through drug failures, board showdowns, and billion-dollar bets. In this episode, she takes us inside the moments that don't make the press release: a phase one cancer patient still alive today, decades after a drug nobody thought would work; a multiple myeloma patient who happened to be trial patient #007 and was actually named James Bond; and the $60,000 milk-budget cut that nearly tanked employee morale company-wide.
In this episode of the podcast we are joined by Dr. Phillip Sharp, Nobel Prize Laureate and Institute Professor at MIT, who shares his story behind the groundbreaking discovery of RNA splicing. He explains how the work ethic and problem solving instinctions he built early on eventually led him to Caltech, and then MIT, where his 1977 discovery changed how we understand gene expression.